We are live on
!
Find out more
KCM
Kynam Capital Management Portfolio holdings
AUM
$1.62B
1-Year Est. Return
138.67%
This Fund
S&P 500
This Quarter
Est. Return
+6.98%
1 Year Est. Return
+138.67%
3 Year Est. Return
+268.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.62B
AUM Growth
+$55.7M
(+3.6%)
Cap. Flow
+$25.7M
Cap. Flow
% of AUM
1.58%
Top 10 Holdings %
Top 10 Hldgs %
70.33%
Holding
44
New
7
Increased
12
Reduced
9
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
UroGen Pharma
URGN
|
+$45.1M |
| 2 |
Beam Therapeutics
BEAM
|
+$34.5M |
| 3 |
Travere Therapeutics
TVTX
|
+$31.4M |
| 4 |
CytomX Therapeutics
CTMX
|
+$30.7M |
| 5 |
Legend Biotech
LEGN
|
+$30.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cogent Biosciences
COGT
|
+$78.6M |
| 2 |
Tyra Biosciences
TYRA
|
+$41.1M |
| 3 |
CG Oncology
CGON
|
+$39.3M |
| 4 |
BioCryst Pharmaceuticals
BCRX
|
+$28.6M |
| 5 |
DVAX
Dynavax Technologies
DVAX
|
+$21.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.19% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Relay Therapeutics
RLAY
$4.02B
| $14.2M | 0.87% |
1,424,259
| – | – |
|
27
Geron
GERN
$911M
| $10.2M | 0.63% |
6,836,318
+3,380,000
| +98% | +$5.14M |
|
28
enGene Therapeutics
ENGN
$122M
| $9.24M | 0.57% |
1,356,843
-136,055
| -9% | -$1.21M |
|
29
Design Therapeutics
DSGN
$736M
| $8.35M | 0.52% |
784,606
| – | – |
|
30
Wave Life Sciences
WVE
$1.12B
| $7M | 0.43% |
965,193
-1,203,912
| -56% | -$15.7M |
|
|
CLYM
31
Climb Bio
CLYM
$735M
| $6.87M | 0.42% |
1,003,341
-25,000
| -2% | -$144K |
|
|
AMRN
32
Amarin Corp
AMRN
$284M
| $6.83M | 0.42% |
472,382
+83,109
| +21% | +$1.24M |
|
33
Biohaven
BHVN
$2.16B
| $5.95M | 0.37% |
702,884
| – | – |
|
34
Prelude Therapeutics
PRLD
$305M
| $5.45M | 0.34% |
1,592,551
+803,684
| +102% | +$2.11M |
|
35
Caribou Biosciences
CRBU
$156M
| $4.76M | 0.29% |
2,503,302
| – | – |
|
36
Alector
ALEC
$164M
| $4.3M | 0.27% |
2,000,000
| – | – |
|
37
ProQR Therapeutics
PRQR
$243M
| $2.54M | 0.16% |
1,566,317
| – | – |
|
|
38
PUT
Travere Therapeutics
TVTX
$5.33B
| $1.63M | 0.1% |
+54,900
| New | +$1.64M |
|
39
Candel Therapeutics
CADL
$700M
| $980K | 0.06% |
+200,000
| New | +$1.09M |
|
|
40
CALL
Beam Therapeutics
BEAM
$2.58B
| – | – |
-937,000
| Closed | -$26M |
|
|
41
CG Oncology
CGON
$6.11B
| – | – |
-945,830
| Closed | -$39.3M |
|
|
DVAX
42
DELISTED
Dynavax Technologies
DVAX
| – | – |
-1,375,632
| Closed | -$21.2M |
|
43
PUT
Omeros
OMER
$709M
| – | – |
-200,000
| Closed | -$3.44M |
|
|
44
Tyra Biosciences
TYRA
$1.82B
| – | – |
-1,564,492
| Closed | -$41.1M |
|
Similar funds
IPW
WIC
HH
TLFA
KCM
PRA
BW
CC
Kynam Capital Management's Q1 2026 Portfolio in Review
As of Q1 2026, Kynam Capital Management held 44 positions worth $1.62B, up 3.6% from $1.57B the previous quarter. Its ten largest holdings account for 70% of the portfolio.
Kynam Capital Management's Q1 2026 filing shows 7 new, 12 increased, 9 reduced and 5 closed positions. Its largest new stake was UroGen Pharma: 2,247,393 shares worth $40.4M. The largest sale was Cogent Biosciences, an estimated $78.6M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier.
- Kynam Capital Management's largest Q1 2026 buy was UroGen Pharma: 2,247,393 shares worth $40.4M.
- Kynam Capital Management added most to Beam Therapeutics in Q1 2026, an estimated $34.5M increase.
- Kynam Capital Management's biggest Q1 2026 reduction was Cogent Biosciences, cutting an estimated $78.6M.
- Kynam Capital Management fully exited Tyra Biosciences in Q1 2026, selling an estimated $41.1M.
- Kynam Capital Management's ten largest holdings make up 70% of its $1.62B portfolio in Q1 2026.
- Kynam Capital Management opened 7 new positions and closed 5 in Q1 2026.
- Kynam Capital Management's portfolio value rose 3.6% quarter-over-quarter to $1.62B.
Based on Kynam Capital Management's 13F filing for Q1 2026, filed 15 May 2026.